Semaglutide Side Effects: Complete Guide to Common and Serious Reactions

Dr. Daniel McGee

Medically Reviewed

Dr. Daniel McGee, D.O.

Family Medicine Doctor

Written by Jake Dickson, NASM-CPT, USAW-L2

Published: May 30, 2026 12 Min Read
A woman self-administering a GLP-1 medication injection into her stomach

Photo Credit: agrobacter / iStock

Key Takeaways

  • Around 90% of semaglutide users experience side effects, but only 7% stop treatment because of them.
  • Nausea, vomiting, and diarrhea are the most frequently reported side effects and tend to peak during dose escalation.
  • Muscle loss and hair shedding are often driven by caloric restriction rather than the drug itself, and both can be reduced with the right diet and exercise habits.
  • Serious complications like pancreatitis and gallbladder issues are rare, but recognizing the warning signs early is critical.
  • Tracking symptoms and staying in contact with your doctor or pharmacist is the best way to manage side effects without stopping treatment prematurely.

For many people, GLP-1s are a life-changing shift; whether to combat diabetes symptoms or manage weight, semaglutide can seem like all upside. But the reality is, semaglutide has side effects.

"GLP-1 side effects are common, but in my experience, they are usually manageable," says Dr. Daniel McGee, board-certified family medicine physician.

If you’re a patient considering, or currently using, FDA-approved medications like Wegovy, Ozempic, or Rybelsus, you need to know the facts.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist. For weight loss, the medication acts primarily in your brain, binding to crucial receptors responsible for appetite signaling and satiety, helping to curb cravings.

As a diabetes management tool, semaglutide also helps keep blood sugar levels in check by stimulating insulin production.

It’s worth mentioning that semaglutide is dosed and marketed differently for each of these purposes. That difference may also influence the prevalence and severity of side effects.

What Causes Semaglutide Side Effects

“The dose makes the poison,” popularly attributed to Swiss physician Paracelus, describes the two sides of semaglutide—it can be incredibly beneficial when dosed and taken properly, but does have side effects as well.

Some side effects simply come with the territory, reported by so many users that you should expect to encounter them on some level. Others are rare, depending on genetic factors, medical contraindications, lifestyle choices, or miscalculating your dosage.

While certain side effects of semaglutide have been characterized as “concerning” by researchers, GLP-1s are not uniquely dangerous. Like all medications, there are risks and benefits.

It’s up to you and your physician to determine whether semaglutide is the right choice for your needs. Before you decide, you should also know how semaglutide side effects pop up in the first place.

Slower Gastric Emptying

One of semaglutide’s primary effects is delayed gastric emptying—it slows down your digestive system, which makes you feel fuller and more satiated after a meal. However, digestive “traffic jams” can elicit stomach-related side effects.

Changes to Appetite and Eating Habits

Beyond the digestive system, semaglutide also takes hold in your brain to influence eating behaviors. Namely, making you less tempted by cravings, especially for flavorful, high-fat, or high-sugar foods.

The real-world outcome here is a calorie deficit; a gap between the energy your body needs to function and what you’re providing it. That deficit is the chief mechanism behind weight loss, but it does have its own downsides as well.

Dose Escalation and Tolerance

Semaglutide users begin their protocols at extremely conservative doses for two reasons:

  • To give the body time to acclimate to the effects of the drug
  • To smoothly arrive at your specific therapeutic dose and not accidentally take too much

This process is called titration. Titrating semaglutide is standard practice, but we do know from research that many side effects tend to be most prevalent during and shortly after titration.

Common Side Effects

Brand-name GLP-1s may feel like the next big thing in health and wellness, but semaglutide is actually a long-studied compound with many years of research into both its benefits and side effects. You can also refer directly to the manufacturer Novo Nordisk’s prescribing information

One stat worth noting: according to foundational data, around 90% of weekly semaglutide users experience some form of “adverse event” or side effect—but only 7% of users have to stop taking semaglutide as a result.

Gastrointestinal Issues

Stomach troubles are the most common category of semaglutide side effects. While it is believed that semaglutide leads to gastrointestinal disorders less than 5% of the time, ”transient, mild-to-moderate” bouts of the following issues are commonplace among GLP-1 drugs:

  • Nausea: 44%
  • Vomiting: 25%
  • Diarrhea: 32%
  • Constipation: 23%
  • Abdominal pain: 10%

Fatigue, Dizziness, Headache

Clinical data does not support the idea that semaglutide directly causes dizziness, headaches, or significant fatigue. That said, anecdotal reports tell a different story. What’s happening here? Remember that semaglutide regulates appetite, making you more likely to end up in a calorie deficit.

Caloric restriction is not the same thing as malnutrition, but both have similar hallmarks over a long enough timescale. Certain studies have shown that even two days of significant calorie deprivation can have “robust effects” on mood. Inadequate hydration, electrolyte, or carbohydrate intake can contribute as well.


GLP-1 side effects can be common, but in my experience, they are usually manageable. The most important thing is to communicate with your doctor or pharmacist rather than just stopping treatment or suffering through it. We can often adjust the dose, stay at a certain dose longer, or even add nausea medication when appropriate. Diet habits matter too. Smaller meals, less greasy food, and stopping when full can make a big difference. If you’re worried about side effects, reach out. These medications are generally well tolerated, and most symptoms can be worked through safely with the right guidance.

Dr. Daniel McGee, Board-certified Family Medicine Physician


A More Guided Way to Start

A More Guided Way to Start

SkinnyRx connects you with a licensed provider who can assess your eligibility, prescribe GLP-1 treatment when appropriate, and support you with ongoing guidance throughout your weight loss journey.

Less-Common Side Effects

The following effects are reported less frequently but are worth understanding before and during treatment. Some have stronger clinical backing than others, and that distinction is noted where relevant.

Reflux and Heartburn

You may experience acid reflux or heartburn on semaglutide. These problems are less commonly reported in the literature, but case studies have demonstrated a potential link between GLP-1-induced vomiting and reflux.

Hair Loss

Semaglutide is also receiving some media attention for potentially exacerbating hair loss. There is a clinical basis; some data indicates up to 15% of users experience shedding on GLP-1s. However, these findings have been rebuffed as sparse and conflicting by other studies.

Although experts acknowledge an association, hair loss on semaglutide is probably caused not by the drug itself but by prolonged caloric restriction and a lack of essential hair-health nutrients like protein and keratin.

Muscle Loss

Similarly, the loss of muscle mass has also been attributed to using GLP-1s. The numbers are more stark than what we know about hair loss, though—one systematic review alleged that up to 40% of total weight loss on GLP-1s can come from muscle rather than fat.

It’s an alarming figure. Muscle mass is essential for metabolic function and physical vitality, particularly among the elderly, obese individuals, or diabetics; the top candidates for GLP-1 use.

The good news is that muscular atrophy on GLP-1s can be mitigated or prevented by lifestyle adjustments. Prioritizing dietary protein, lifting weights, and tracking calories to ensure you’re in an effective, but not excessive, deficit goes a long way.

Palate Changes

Anecdotal reports on sites like Reddit spin a troubling tale. Semaglutide may do more than curb cravings—it can alter the sensory enjoyment of food. This phenomenon has been documented clinically, but science is still exploring the frontier of GLP-1 potential, as well as side effects.

Changes to the palate likely originate in the brain, where semaglutide works to alter your relationship with food. Plainly, GLP-1 drugs appear to dim the urge to succumb to impulse—eating when you’re not hungry, or even reaching for a cigarette.

Contemporary clinical trials are exploring how this “side effect” might help treat certain forms of addiction. Nonetheless, palate changes on Ozempic or Wegovy, like most side effects, are temporary and likely to dissipate once you stop taking the drug.

Serious Issues and Warning Signs

Most semaglutide side effects are mild or moderate. Some warrant greater scrutiny, or may even deter you from taking the medication altogether. Here are the facts.

Pancreatitis Symptoms

Acute pancreatitis has been reported in less than 1% of semaglutide users. However, some case reports have pegged semaglutide as the “likely causative factor” for acute pancreatitis, based on changes in lipase levels.

Likelihood aside, it’s worth taking these reports seriously—there have been deaths related to semaglutide’s exacerbation of pancreatitis symptoms.

Gallbladder Symptoms

2.6% of semaglutide users may experience “gallbladder-related disorders.” Scientists are still investigating the underpinning mechanisms between GLP-1s and gallstone formation (among other symptoms).

Dehydration & Kidney Concerns

Dehydration can occur frequently for semaglutide users as a downstream consequence of gastrointestinal issues that make it difficult to drink water, or having hydration caught up in the diminished “food noise” folks typically experience.

No matter the cause, scientists stress that dehydration “necessitates special attention” as it may contribute to renal failure (in less than half a percent of users) and other kidney issues.

Allergic Reactions

Some people can have adverse allergic reactions to semaglutide, according to clinical case reports. These reactions can include dermal hypersensitivity, blisters, or rashes lasting multiple weeks. Like most side effects, ceasing semaglutide led to the symptoms dissipating.

Thyroid Tumor Warning Language

The prescribing information for Ozempic prominently highlights the risk of developing thyroid tumors:

“OZEMPIC is contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2),”—these warnings concern rare diseases and have only been observed in rodent studies. Thyroid tumors caused by semaglutide have not been identified in human trials.

How To Track Semaglutide Side Effects

There are several ways to keep tabs on semaglutide side effects. No matter your method, it’s important to be vigilant about how prescription medications affect your well-being. The best method is to keep a symptom journal. Track:

  • When the side effect occurred
  • How long it lasted
  • How severe it was
  • The dosage you took prior

Once you have a sense of how severe your side effects are, when they started, and how often you experience them, you can take this information to your physician or pharmacist for clarity or assistance.

The most important thing is to communicate with your doctor or pharmacist rather than just stopping treatment or suffering through it,” Dr. McGee adds. “We can often adjust the dose, stay at a certain dose longer, or even add nausea medication when appropriate.”

While your doctor may have a more comprehensive view of your total-body health, pharmacists are often easier to reach and have more timely information about pharmaceutical side effects. If you can’t reach your doctor on short notice, don’t hesitate to call your pharmacy.

Bottom Line

Semaglutide side effects are real, and it's worth going in with clear expectations. Most people experience something, but that doesn't mean most people have a bad experience.

The majority of side effects are tied to changes in digestion and appetite. They tend to be most disruptive early in treatment, particularly during dose escalation, and ease up over time for most users.

The more serious concerns, like pancreatitis or gallbladder issues, are rare. It's worth knowing the warning signs so you can act quickly if something feels off.

What makes the biggest difference is staying in communication with your doctor or pharmacist. Don't stop treatment or push through it silently. Tracking your symptoms gives them something concrete to work with, and they can often make adjustments.

Like any medication, semaglutide involves tradeoffs. Understanding those tradeoffs, with your doctor's guidance, puts you in a better position to make the right call for your health.

Frequently Asked Questions

The most common semaglutide side effects are gastrointestinal. Stomach issues like nausea, vomiting, or cramps are commonly reported in a majority of users, usually occurring after an injection or throughout the titration process.


Yes. The majority of side effects from semaglutide are tied to the medication; clinical data suggest that when you hop off, side effects drastically diminish or disappear altogether.


Semaglutide side effects can become serious if left untreated. Most GLP-1 side effects are temporary and sporadic. If your symptoms are persistent and/or worsen over time, you may want to seek medical attention.


Yes, in rare cases, semaglutide may cause acute pancreatitis. Trial data suggests this occurs in less than 1% of users, but it is a consideration if you have pre-existing issues or a family history of pancreatitis.


Semaglutide may potentially affect the gallbladder or lead to the formation of gallstones. Available data indicate this risk is quite low and is still being studied.


Not necessarily. Nausea is a common side effect of semaglutide, and can arise from ramping up your dosage or if you’re injecting the medication and are squeamish about needles. Nausea doesn’t necessarily mean you need to stop or change your dose unless it is persistent or interferes with your day-to-day life.

A More Guided Way to Start

A More Guided Way to Start

SkinnyRx connects you with a licensed provider who can assess your eligibility, prescribe GLP-1 treatment when appropriate, and support you with ongoing guidance throughout your weight loss journey.


  1. Pillarisetti L, Agrawal DK. Semaglutide: Double-edged Sword with Risks and Benefits. Arch Intern Med Res. 2025;8(1):1-13. doi: 10.26502/aimr.0189. Epub 2025 Jan 10. PMID: 39902055; PMCID: PMC11790292: https://pmc.ncbi.nlm.nih.gov/articles/PMC11790292/
  2. Kommu S, Whitfield P. Semaglutide. [Updated 2024 Feb 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK603723/
  3. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185: https://www.nejm.org/doi/10.1056/NEJMoa2032183
  4. Novo Nordisk Inc. Ozempic (semaglutide) injection, for subcutaneous use: prescribing information [Internet]. Plainsboro (NJ): Novo Nordisk Inc.; 2026 May [cited 2026 May 30]. 19 p. Available from: https://www.novo-pi.com/ozempic.pdf
  5. Sillassen CDB, Petersen JJ, Faltermeier P, Yucel D, Siddiqui F, Andersen RK, et al. The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis. BMC Med. 2025 Nov 24;23(1):654. doi: 10.1186/s12916-025-04486-0. PMID: 41286875; PMCID: PMC12642075: https://pmc.ncbi.nlm.nih.gov/articles/PMC12642075/
  6. Kashima S, Moriichi K, Fujiya M. Severe reflux oesophagitis caused by repeated vomiting due to glucagon-like peptide-1 receptor agonist. BMJ Case Rep. 2025 Aug 4;18(8):e266368. doi: 10.1136/bcr-2025-266368. PMID: 40759494; PMCID: PMC12322966: https://pmc.ncbi.nlm.nih.gov/articles/PMC12322966/
  7. Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study. J Am Acad Dermatol. 2025 May;92(5):1141-1143. doi: 10.1016/j.jaad.2025.01.046. Epub 2025 Jan 23. PMID: 39863171: https://pubmed.ncbi.nlm.nih.gov/39863171/
  8. Desai DD, Sikora M, Nohria A, Bordone L, Caplan AS, Shapiro J, Lo Sicco KI. GLP-1 agonists and hair loss: a call for further investigation. Int J Dermatol. 2024 Sep;63(9):1128-1130. doi: 10.1111/ijd.17246. Epub 2024 May 13. PMID: 38741261: https://pubmed.ncbi.nlm.nih.gov/38741261/
  9. Alsuwailem OA, Alanazi R, Almutairi HM, Asiree RH, Almutairi W, Almutairi TM, et al. Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. Cureus. 2025 Sep 16;17(9):e92454. doi: 10.7759/cureus.92454. PMID: 41111833; PMCID: PMC12530271: https://pmc.ncbi.nlm.nih.gov/articles/PMC12530271/
  10. Haykal D. Alopecia and Semaglutide: Connecting the Dots for Patient Safety. J Cosmet Dermatol. 2025 Mar;24(3):e70125. doi: 10.1111/jocd.70125. PMID: 40087997; PMCID: PMC11909624: https://pmc.ncbi.nlm.nih.gov/articles/PMC11909624/
  11. Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother. 2024 Apr;25(5):611-619. doi: 10.1080/14656566.2024.2343092. Epub 2024 Apr 18. PMID: 38629387: http://tandfonline.com/doi/full/10.1080/14656566.2024.2343092
  12. Kapan A, Moser O, Felsinger R, Waldhoer T, Haider S. Real-world insights into incretin-based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross-sectional study. Diabetes Obes Metab. 2025 Sep;27(9):5008-5018. doi: 10.1111/dom.16548. Epub 2025 Jun 24. PMID: 40552449; PMCID: PMC12326916: https://pmc.ncbi.nlm.nih.gov/articles/PMC12326916/
  13. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data. Ann Intern Med. 2024 Aug;177(8):1016-1027. doi: 10.7326/M23-2718. Epub 2024 Jul 30. PMID: 39074369; PMCID: PMC12721465: https://pmc.ncbi.nlm.nih.gov/articles/PMC12721465/
  14. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT07218354, Cessation or reduction of alcohol consumption in veterans: a randomized, double-blind, placebo-controlled phase 3 trial to evaluate the efficacy and safety of a GLP-1 receptor agonist semaglutide in U.S. veterans with alcohol use disorder; 2026 Apr [cited 2026 May 30]. Available from: https://clinicaltrials.gov/study/NCT07218354
  15. Hughes K, Sumaruth YRK, Mohammed E, Sant Bakshsingh V. Acute Pancreatitis Likely Due to Semaglutide. Cureus. 2024 Sep 21;16(9):e69844. doi: 10.7759/cureus.69844. PMID: 39308839; PMCID: PMC11416045: https://pmc.ncbi.nlm.nih.gov/articles/PMC11416045/
  16. Dagher C, Jailani M, Akiki M, Siddique T, Saleh Z, Nadler E. Semaglutide-Induced Acute Pancreatitis Leading to Death After Four Years of Use. Cureus. 2024 Sep 19;16(9):e69704. doi: 10.7759/cureus.69704. PMID: 39429379; PMCID: PMC11489890: https://pmc.ncbi.nlm.nih.gov/articles/PMC11489890/
  17. Ramírez-Mejía MM, Ponciano-Rodriguez G, Eslam M, Méndez-Sánchez N. GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications. Ther Adv Endocrinol Metab. 2025 Dec 23;16:20420188251406456. doi: 10.1177/20420188251406456. PMID: 41459016; PMCID: PMC12739101: https://pmc.ncbi.nlm.nih.gov/articles/PMC12739101/
  18. Rehman SU, Kolanu ND, Mushtaq MM, Ali H, Ahmed Z, Mushtaq M, et al. Assessing the Renal Outcomes of Semaglutide in Diabetic Kidney Disease: A Systematic Review. Cureus. 2024 Jul 7;16(7):e64038. doi: 10.7759/cureus.64038. PMID: 39114239; PMCID: PMC11303570: https://pubmed.ncbi.nlm.nih.gov/39114239/
  19. Ouellette S, Frias G, Shah R, Alamgir M, Wassef C. Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports. J Drugs Dermatol. 2023 Apr 1;22(4):413-416. doi: 10.36849/JDD.6550. PMID: 37026881: https://pubmed.ncbi.nlm.nih.gov/37026881/
Jake Dickson, NASM-CPT, USAW-L2

By Jake Dickson, NASM-CPT, USAW-L2

Contributing Author

Jake holds a B.S. in Exercise Science from UNC Wilmington and began his career as a personal trainer and weightlifting coach. In recent years, he’s moved behind the page as a writer and editor, contributing hundreds of articles and being featured as a subject matter expert. Today, Jake’s goal remains the same: to empower people to change their lives by bringing heady scientific topics down to ground level.